

Mark J Mckeage

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5903262/mark-j-mckeage-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

3,922
citations

33
h-index

60
g-index

99
ext. papers

4,314
ext. citations

5.8
avg, IF

5.26
L-index

#	Paper	IF	Citations
94	Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2965-71	2.2	230
93	Comparative adverse effect profiles of platinum drugs. <i>Drug Safety</i> , 1995 , 13, 228-44	5.1	226
92	Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. <i>Coordination Chemistry Reviews</i> , 2002 , 232, 127-135	23.2	212
91	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 343-50	3.5	176
90	In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 303-10	4.2	163
89	Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. <i>Cancer</i> , 2010 , 116, 1859-71	6.4	124
88	Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. <i>Journal of Inorganic Biochemistry</i> , 1999 , 77, 105-10	4.2	120
87	Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2008 , 99, 2006-12	8.7	108
86	Lobaplatin: a new antitumour platinum drug. <i>Expert Opinion on Investigational Drugs</i> , 2001 , 10, 119-28	5.9	108
85	Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents. <i>Coordination Chemistry Reviews</i> , 1999 , 185-186, 823-836	23.2	107
84	Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 338, 537-47	4.7	103
83	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1357-1367	8.9	100
82	Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 391-9	3.5	87
81	5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. <i>Clinical Cancer Research</i> , 2006 , 12, 1776-84	12.9	86
80	Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 51, 43-52	3.5	85
79	Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. <i>British Journal of Cancer</i> , 2001 , 85, 1219-25	8.7	83
78	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 451-8	3.5	83

77	Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m ² combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009 , 65, 192-7	5.9	80
76	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. <i>Journal of Structural Biology</i> , 2015 , 192, 539-544	3.4	73
75	Rapid biotransformation of satraplatin by human red blood cells in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 9-15	3.5	70
74	Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 483-90	3.5	69
73	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 1998-2005	12.9	67
72	Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 1090-8	8.3	56
71	Antitumor activity of gold(i), silver(i) and copper(i) complexes containing chiral tertiary phosphines. <i>Metal-Based Drugs</i> , 1998 , 5, 217-23		53
70	A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. <i>BMC Cancer</i> , 2011 , 11, 432	4.8	47
69	Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. <i>Current Cancer Drug Targets</i> , 2012 , 12, 962-86	2.8	46
68	cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. <i>Journal of Inorganic Biochemistry</i> , 2001 , 85, 209-17	4.2	45
67	Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 847-56	3.5	44
66	PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. <i>BMC Cancer</i> , 2012 , 12, 496	4.8	42
65	New-generation platinum drugs in the treatment of cisplatin-resistant cancers. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 1033-46	5.9	40
64	Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. <i>BMC Cancer</i> , 2010 , 10, 451	4.8	37
63	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. <i>Targeted Oncology</i> , 2018 , 13, 89-98	5	37
62	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1255-1265	8.9	36
61	Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. <i>British Journal of Cancer</i> , 1993 , 67, 996-1000	8.7	33
60	Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 3508-15	8.3	32

59	Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 837, 29-34	3.2	32
58	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 28, 409-13	3.5	31
57	Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. <i>Biochemical Pharmacology</i> , 2013 , 85, 207-15	6	30
56	The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 23-9	5.9	29
55	Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. <i>Molecular Pain</i> , 2010 , 6, 53	3.4	27
54	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. <i>PLoS ONE</i> , 2015 , 10, e0130727	3.7	26
53	Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. <i>NeuroToxicology</i> , 2007 , 28, 1092-8	4.4	25
52	Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. <i>Journal of Neurochemistry</i> , 2015 , 135, 1099-112	6	24
51	Gold opens mitochondrial pathways to apoptosis. <i>British Journal of Pharmacology</i> , 2002 , 136, 1081-2	8.6	23
50	Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. <i>Journal of Analytical Atomic Spectrometry</i> , 1999 , 14, 953-956	3.7	23
49	Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue. <i>Molecular Pain</i> , 2009 , 5, 66	3.4	22
48	Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. <i>Journal of Thoracic Disease</i> , 2010 , 2, 199-204	2.6	22
47	Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl ₂ in the blood plasma of colorectal cancer patients. <i>Journal of Analytical Atomic Spectrometry</i> , 2008 , 23, 881	3.7	21
46	Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 661-9	3.5	19
45	Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. <i>BMC Cancer</i> , 2013 , 13, 495	4.8	18
44	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. <i>Frontiers in Oncology</i> , 2014 , 4, 221	5.3	18
43	Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008 , 35, 1440-6	3	18
42	5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). <i>American Journal of Cancer</i> , 2006 , 5, 155-162		18

41	Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. <i>British Journal of Cancer</i> , 2003 , 88, 1942-7	8.7	18
40	Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 497-503	3.5	17
39	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone oxime)dichloroplatinum(II) and investigations into its low cytotoxicity. <i>Journal of Biological Inorganic Chemistry</i> , 2000 , 5, 675-81	3.7	16
38	Non-surgical aspects of ovarian cancer. <i>Lancet, The</i> , 1994 , 343, 335-340	4.0	16
37	Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. <i>British Journal of Cancer</i> , 1994 , 69, 1-7	8.7	16
36	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALK-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 609-617	8.9	15
35	Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. <i>Journal of Inorganic Biochemistry</i> , 2017 , 177, 249-258	4.2	13
34	The Effects of Synthetically Modified Natural Compounds on ABC Transporters. <i>Pharmaceutics</i> , 2018 , 10,	6.4	13
33	Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. <i>Drugs</i> , 2007 , 67, 859-69	12.1	13
32	New platinum agents. A comparison in ovarian cancer. <i>Drugs and Aging</i> , 1994 , 5, 85-95	4.7	13
31	ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. <i>Future Oncology</i> , 2010 , 6, 1537-43	3.6	12
30	Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl)ethane-1,2-diamine and ethane-1,2-diamine-N,N-diacetic acid. <i>Journal of Inorganic Biochemistry</i> , 2002 , 91, 205-11	4.2	12
29	Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. <i>Scientific Reports</i> , 2019 , 9, 2245	4.9	11
28	Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2012 , 2, 985-993		11
27	Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials 2009 , 50, 2553-9		11
26	Emerging roles of metal solute carriers in cancer mechanisms and treatment. <i>Biopharmaceutics and Drug Disposition</i> , 2014 , 35, 450-62	1.7	10
25	EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. <i>Targeted Oncology</i> , 2017 , 12, 663-675	5	10
24	Clinical trials of vascular disrupting agents in advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2011 , 12, 143-7	4.9	10

23	Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004 , 31, 677-82	3	10
22	Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. <i>Oncotarget</i> , 2017 , 8, 101437-101451	3.3	10
21	Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013 , 40, 371-8	3	9
20	Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1479-1490	5.5	9
19	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. <i>Cancers</i> , 2019 , 11,	6.6	8
18	Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. <i>Targeted Oncology</i> , 2020 , 15, 279-299	5	8
17	Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 28, 414-9	3.5	7
16	New Platinum Drugs 1993 , 169-212		7
15	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 25-35	3.5	6
14	Reply to E.S. Wang et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 761-762	2.2	6
13	Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. <i>New England Journal of Medicine</i> , 1993 , 328, 140-1	59.2	6
12	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. <i>Cancer Epidemiology</i> , 2018 , 57, 24-32	2.8	6
11	Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation. <i>Scientific Reports</i> , 2017 , 7, 4073	4.9	5
10	Selective antitumour activity of metal complexes of bidentate pyridylphosphines. <i>Journal of Inorganic Biochemistry</i> , 1997 , 67, 154	4.2	5
9	Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007 , 3, 99-105	1.9	5
8	Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. <i>Internal Medicine Journal</i> , 2020 , 50, 716-725	1.6	5
7	The Clinical Development of the Oral Platinum Anticancer Agent JM216 1996 , 83-89		4
6	Mass balance, excretion and metabolism of [¹⁴ C] ASA404 in cancer patients in a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1145-54	3.5	3

5	Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity. <i>Clinical Neurophysiology</i> , 2020 , 131, 343-344	4.3	3
4	Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. <i>Cancer Investigation</i> , 1999 , 17, 479-85	2.1	2
3	A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 29, 201-6	3.5	2
2	Osimertinib in NSCLC: Real-World Data From New Zealand. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100022	1.4	1
1	Therapeutic targeting of tumor angiogenesis: how far have we come?. <i>Clinical Investigation</i> , 2014 , 4, 1113-1122		